Related Experiment Video
Updated: May 2, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression
Michael Dews1, Grace S Tan, Stacy Hultine
1Affiliations of authors: Division of Cancer Pathobiology, Center for Childhood Cancer Research (MD, GST, SH, AT-T) and Center for Biomedical Informatics (PR), Children's Hospital of Philadelphia, Philadelphia, PA; Cancer Biology Graduate Program (JC, EKD, AT-T) and Department of Pathology & Laboratory Medicine (AT-T), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Division of Experimental Pathology, Beth Israel Deaconess Medical Center (JL) and Department of Medical Oncology, Dana-Farber Cancer Institute (AB), Harvard Medical School, Boston, MA.
Background:
The c-Myc oncoprotein is activated in the majority of colorectal cancers (CRCs), whereas the TGF-β pathway is frequently affected by loss-of-function mutations, for example in SMAD2/3/4 genes. The canonical model places Myc downstream of inhibitory TGF-β signaling. However, we previously demonstrated that Myc also inhibits TGF-β signaling through the miR-17~92 microRNA cluster, raising the question about functional relationships between these two pathways.
Methods:
We engineered a series of genetically complex murine and human CRC cell lines in which Myc and TGF-β activities could be manipulated simultaneously. This was achieved through retroviral expression of the Myc-estrogen receptor fusion protein and through Smad4 short hairpin RNA knockdown. Cell lines thus modified were injected subcutaneously in immunocompromised mice, and the resultant tumors (n = 5-10 per treatment group) were analyzed for overall growth and neovascularization. Additionally, the distribution of MYC and TGF-β pathway mutations was analyzed in previously profiled human CRC samples.
Results:
In kras-mutated/trp53-deleted murine colonocytes, either Myc activation or TGF-β inactivation increased tumor sizes and microvascular densities approximately 1.5- to 2.5-fold, chiefly through downregulation of thrombospondin-1 and related type I repeat-containing proteins. Combining Myc activation with TGF-β inactivation did not further accelerate tumorigenesis. This redundancy and the negative effect of TGF-β signaling on angiogenesis were also demonstrated using xenografts of human CRC cell lines. Furthermore, the analysis of the Cancer Genome Atlas data revealed that in CRC without microsatellite instability, overexpression of Myc and inactivation of Smads (including acquired mutations in SMAD2) are mutually exclusive, with odds ratio less than 0.1.
Conclusions:
In human CRC, gain-of-function alterations in Myc and loss-of-function alterations in TGF-β exhibit a masking epistatic interaction and are functionally redundant.
Insights
Myc and TGF-β pathways interact in colorectal cancer (CRC). Activating Myc or inactivating TGF-β similarly boosts tumor growth, showing functional redundancy in CRC development.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Colorectal cancer (CRC) frequently involves c-Myc activation and TGF-β pathway dysfunction.
- Canonical models place Myc downstream of TGF-β, but Myc can also inhibit TGF-β via microRNAs.
- The functional relationship between Myc and TGF-β in CRC remains unclear.
Purpose of the Study:
- To investigate the functional relationship between Myc and TGF-β signaling in colorectal cancer.
- To determine if Myc and TGF-β pathway alterations interact or are redundant in CRC tumorigenesis.
Main Methods:
- Engineered murine and human CRC cell lines with inducible Myc and TGF-β pathway manipulation.
- Utilized retroviral expression of Myc-estrogen receptor fusion and Smad4 short hairpin RNA.
- Analyzed tumor growth, neovascularization in vivo, and mutation distribution in human CRC samples (Cancer Genome Atlas).
Main Results:
- Myc activation or TGF-β inactivation independently increased tumor size and microvascular density in murine colonocytes (1.5-2.5 fold).
- Combined Myc activation and TGF-β inactivation showed no additive effect, indicating functional redundancy.
- Human CRC data revealed mutually exclusive alterations between Myc overexpression and Smad inactivation (odds ratio < 0.1).
Conclusions:
- Gain-of-function alterations in Myc and loss-of-function alterations in TGF-β exhibit a masking epistatic interaction in human CRC.
- These two pathways are functionally redundant in driving colorectal cancer progression.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
07:49Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
Related Concept Videos
TGF - β Signaling Pathway
Mitogens and the Cell Cycle
Regulation of Angiogenesis and Blood Supply